Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
2021 · Genome Medicine · 14 citations
https://doi.org/10.1186/s13073-021-00926-7
S
Swetlana Ladigan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
21
Papers
291
Citations
9
h-index
9
i10-index
Swetlana Ladigan is an academic researcher from University Hospitals of the Ruhr-University of Bochum. The author has contributed to research in topics: Colorectal Cancer Treatments and Studies & Cancer Genomics and Diagnostics & Lung Cancer Treatments and Mutations. The author has an h-index of 9, co-authored 18 publications.
Papers by this author
worksAdditional file 6 of Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
2021 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.14998919
Additional file 1 of Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
2021 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.14998901
Additional file 3 of Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
2021 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.14998910
Additional file 7 of Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
2021 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.14998925
Additional file 5 of Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
2021 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.14998916
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat